Watch out Eli Lil­ly, Ab­b­Vie and Bio­gen: 7 new block­busters are on their way to shake things up

Every year a se­lect group of new drugs promise not to just add an ex­tra op­tion for pa­tients. Some of these block­buster-to-be drugs are ex­pect­ed to dra­mat­i­cal­ly re­shape ex­ist­ing mar­kets, of­ten by steal­ing away more than their share from the ther­a­pies that al­ready dom­i­nate in a field.

Here are 7 be­ing billed as block­buster buster.

The an­a­lysts at Cortel­lis didn’t just fore­cast 2023 sales for the most promis­ing new drugs slat­ed to win an ap­proval this year, or al­ready prepped for launch. They al­so cal­cu­lat­ed how they would do against the dom­i­nant drugs in their class. And many times their suc­cess will weigh heav­i­ly on the chart-top­ping drugs in their field.

Here’s a sum­ma­ry, based on the new re­port.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER